4//SEC Filing
Gheuens Sarah 4
Accession 0001439222-25-000073
CIK 0001439222other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 4:01 PM ET
Size
8.9 KB
Accession
0001439222-25-000073
Insider Transaction Report
Form 4
Gheuens Sarah
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted stock units
2025-07-01−8,374→ 8,375 total→ Common stock (8,374 underlying) - Sale
Common stock
2025-07-01$34.17/sh−4,091$139,789→ 61,271 total - Exercise/Conversion
Common stock
2025-07-01+8,374→ 65,362 total
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001881190
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 4:01 PM ET
- Size
- 8.9 KB